Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America

Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease Work Group, 2013, KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease, Kidney Int Suppl, 3, 1

Gupta, 2005, Guidelines for the management of chronic kidney disease in HIV-infected patients: recommendations of the HIV Medicine Association of the Infectious Diseases Society of America, Clin Infect Dis, 40, 1559, 10.1086/430257

Guyatt, 2008, GRADE: an emerging consensus on rating quality of evidence and strength of recommendations, BMJ, 336, 924, 10.1136/bmj.39489.470347.AD

Gardner, 2003, Development of proteinuria or elevated serum creatinine and mortality in HIV-infected women, J Acquir Immune Defic Syndr, 32, 203, 10.1097/00126334-200302010-00013

Choi, 2007, Racial differences in end-stage renal disease rates in HIV infection versus diabetes, J Am Soc Nephrol, 18, 2968, 10.1681/ASN.2007040402

Guyatt, 2011, GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology, J Clin Epidemiol, 64, 380, 10.1016/j.jclinepi.2010.09.011

Chow, 2012, IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults, Clin Infect Dis, 54, e72, 10.1093/cid/cis370

National Kidney Foundation Kidney Disease Outcome Quality Initiative Advisory Board, 2002, K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney Disease Outcome Quality Initiative, Am J Kidney Dis, 39, S1

Astor, 2011, Is there something better than the best marker of kidney function?, J Am Soc Nephrol, 22, 1779, 10.1681/ASN.2011080844

Gansevoort, 2011, Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts, Kidney Int, 80, 93, 10.1038/ki.2010.531

van der Velde, 2011, Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts, Kidney Int, 79, 1341, 10.1038/ki.2010.536

Matsushita, 2010, Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis, Lancet, 375, 2073, 10.1016/S0140-6736(10)60674-5

Stevens, 2006, Assessing kidney function—measured and estimated glomerular filtration rate, N Engl J Med, 354, 2473, 10.1056/NEJMra054415

Filler, 2005, Cystatin C as a marker of GFR—history, indications, and future research, Clin Biochem, 38, 1, 10.1016/j.clinbiochem.2004.09.025

Inker, 2012, Estimating glomerular filtration rate from serum creatinine and cystatin C, N Engl J Med, 367, 20, 10.1056/NEJMoa1114248

Peralta, 2011, Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality, JAMA, 305, 1545, 10.1001/jama.2011.468

Manetti, 2005, Thyroid function differently affects serum cystatin C and creatinine concentrations, J Endocrinol Invest, 28, 346, 10.1007/BF03347201

Risch, 2001, Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients, Clin Chem, 47, 2055, 10.1093/clinchem/47.11.2055

Keller, 2007, Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study, Kidney Int, 71, 239, 10.1038/sj.ki.5002042

Knight, 2004, Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement, Kidney Int, 65, 1416, 10.1111/j.1523-1755.2004.00517.x

Mauss, 2008, Cystatin C as a marker of renal function is affected by HIV replication leading to an underestimation of kidney function in HIV patients, Antivir Ther, 13, 1091, 10.1177/135965350801300810

Estrella, 2011, Chronic kidney disease and estimates of kidney function in HIV infection: a cross-sectional study in the Multicenter AIDS Cohort Study, J Acquir Immune Defic Syndr, 57, 380, 10.1097/QAI.0b013e318222f461

Bhasin, 2013, HIV viremia and T-cell activation differentially affect the performance of glomerular filtration rate equations based on creatinine and cystatin C, PLoS One, 8, e82028, 10.1371/journal.pone.0082028

Shlipak, 2013, Cystatin C versus creatinine in determining risk based on kidney function, N Engl J Med, 369, 932, 10.1056/NEJMoa1214234

Shlipak, 2006, Cystatin C and prognosis for cardiovascular and kidney outcomes in elderly persons without chronic kidney disease, Ann Intern Med, 145, 237, 10.7326/0003-4819-145-4-200608150-00003

Shlipak, 2005, Cystatin C and the risk of death and cardiovascular events among elderly persons, N Engl J Med, 352, 2049, 10.1056/NEJMoa043161

Choi, 2010, Cystatin C, albuminuria, and 5-year all-cause mortality in HIV-infected persons, Am J Kidney Dis, 56, 872, 10.1053/j.ajkd.2010.05.019

Inker, 2012, Performance of creatinine and cystatin C GFR estimating equations in an HIV-positive population on antiretrovirals, J Acquir Immune Defic Syndr, 61, 302, 10.1097/QAI.0b013e31826a6c4f

Gagneux-Brunon, 2013, Performance of creatinine and cystatin C-based glomerular filtration rate estimating equations in a European HIV-positive cohort, AIDS, 27, 1573, 10.1097/QAD.0b013e32835fac30

Levey, 2009, A new equation to estimate glomerular filtration rate, Ann Intern Med, 150, 604, 10.7326/0003-4819-150-9-200905050-00006

Gerstein, 2001, Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals, JAMA, 286, 421, 10.1001/jama.286.4.421

Siedner, 2008, Poor validity of urine dipstick as a screening tool for proteinuria in HIV-positive patients, J Acquir Immune Defic Syndr, 47, 261, 10.1097/QAI.0b013e31815ac4ad

Eknoyan, 2003, Proteinuria and other markers of chronic kidney disease: a position statement of the National Kidney Foundation (NKF) and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Am J Kidney Dis, 42, 617, 10.1016/S0272-6386(03)00826-6

Fernando, 2008, Prevalence of chronic kidney disease in an urban HIV infected population, Am J Med Sci, 335, 89, 10.1097/MAJ.0b013e31812e6b34

Mocroft, 2007, Chronic renal failure among HIV-1-infected patients, AIDS, 21, 1119, 10.1097/QAD.0b013e3280f774ee

Wyatt, 2007, Chronic kidney disease in HIV infection: an urban epidemic, AIDS, 21, 2101, 10.1097/QAD.0b013e3282ef1bb4

Sorli, 2008, Chronic kidney disease prevalence and risk factors among HIV-infected patients, J Acquir Immune Defic Syndr, 48, 506, 10.1097/QAI.0b013e31817bbecb

Yanik, 2010, HIV and proteinuria in an injection drug user population, Clin J Am Soc Nephrol, 5, 1836, 10.2215/CJN.01030210

Szczech, 2007, Microalbuminuria in HIV infection, AIDS, 21, 1003, 10.1097/QAD.0b013e3280d3587f

Kalayjian, 2008, Suppression of HIV-1 replication by antiretroviral therapy improves renal function in persons with low CD4 cell counts and chronic kidney disease, AIDS, 22, 481, 10.1097/QAD.0b013e3282f4706d

Choi, 2010, Association between kidney function and albuminuria with cardiovascular events in HIV-infected persons, Circulation, 121, 651, 10.1161/CIRCULATIONAHA.109.898585

Gupta, 2009, The effects of HIV type-1 viral suppression and non-viral factors on quantitative proteinuria in the highly active antiretroviral therapy era, Antivir Ther, 14, 543, 10.1177/135965350901400406

Baekken, 2008, Microalbuminuria associated with indicators of inflammatory activity in an HIV-positive population, Nephrol Dial Transplant, 23, 3130, 10.1093/ndt/gfn236

Lucas, 2008, Chronic kidney disease incidence, and progression to end-stage renal disease, in HIV-infected individuals: a tale of two races, J Infect Dis, 197, 1548, 10.1086/587994

Lucas, 2007, End-stage renal disease and chronic kidney disease in a cohort of African-American HIV-infected and at-risk HIV-seronegative participants followed between 1988 and 2004, AIDS, 21, 2435, 10.1097/QAD.0b013e32827038ad

Mocroft, 2010, Estimated glomerular filtration rate, chronic kidney disease and antiretroviral drug use in HIV-positive patients, AIDS, 24, 1667, 10.1097/QAD.0b013e328339fe53

Tordato, 2011, Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure, HIV Med, 12, 4, 10.1111/j.1468-1293.2010.00855.x

Orlando, 2006, Antiretroviral treatment and age-related comorbidities in a cohort of older HIV-infected patients, HIV Med, 7, 549, 10.1111/j.1468-1293.2006.00420.x

Choi, 2010, Long-term clinical consequences of acute kidney injury in the HIV-infected, Kidney Int, 78, 478, 10.1038/ki.2010.171

Tsui, 2009, Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study, Am J Kidney Dis, 54, 43, 10.1053/j.ajkd.2009.02.009

Wyatt, 2008, The impact of hepatitis C virus coinfection on HIV-related kidney disease: a systematic review and meta-analysis, AIDS, 22, 1799, 10.1097/QAD.0b013e32830e0152

Astor, 2011, Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts, Kidney Int, 79, 1331, 10.1038/ki.2010.550

Longenecker, 2009, HIV viremia and changes in kidney function, AIDS, 23, 1089, 10.1097/QAD.0b013e32832a3f24

Kalayjian, 2012, Risk factors for chronic kidney disease in a large cohort of HIV-1 infected individuals initiating antiretroviral therapy in routine care, AIDS, 26, 1907, 10.1097/QAD.0b013e328357f5ed

Berliner, 2008, Observations on a cohort of HIV-infected patients undergoing native renal biopsy, Am J Nephrol, 28, 478, 10.1159/000112851

Freedman, 1999, Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy, Am J Kidney Dis, 34, 254, 10.1016/S0272-6386(99)70352-5

Achhra, 2010, Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients, AIDS, 24, 1877, 10.1097/QAD.0b013e32833b1b26

Baker, 2008, CD4+ count and risk of non-AIDS diseases following initial treatment for HIV infection, AIDS, 22, 841, 10.1097/QAD.0b013e3282f7cb76

Choi, 2007, The impact of HIV on chronic kidney disease outcomes, Kidney Int, 72, 1380, 10.1038/sj.ki.5002541

Lucas, 2004, Highly active antiretroviral therapy and the incidence of HIV-1-associated nephropathy: a 12-year cohort study, AIDS, 18, 541, 10.1097/00002030-200402200-00022

Szczech, 2004, The clinical epidemiology and course of the spectrum of renal diseases associated with HIV infection, Kidney Int, 66, 1145, 10.1111/j.1523-1755.2004.00865.x

Kao, 2008, MYH9 is associated with nondiabetic end-stage renal disease in African Americans, Nat Genet, 40, 1185, 10.1038/ng.232

Kopp, 2008, MYH9 is a major-effect risk gene for focal segmental glomerulosclerosis, Nat Genet, 40, 1175, 10.1038/ng.226

Genovese, 2010, Association of trypanolytic ApoL1 variants with kidney disease in African Americans, Science, 329, 841, 10.1126/science.1193032

Tzur, 2010, Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene, Hum Genet, 128, 345, 10.1007/s00439-010-0861-0

Rosset, 2011, The population genetics of chronic kidney disease: insights from the MYH9-APOL1 locus. Nature reviews, Nephrology, 7, 313

Wyatt, 2008, HIV-associated nephropathy: clinical presentation, pathology, and epidemiology in the era of antiretroviral therapy, Semin Nephrol, 28, 513, 10.1016/j.semnephrol.2008.08.005

Symeonidou, 2009, Imaging features of renal pathology in the human immunodeficiency virus-infected patient, Semin Ultrasound CT MR, 30, 289, 10.1053/j.sult.2009.03.008

Rao, 1991, Clinical features of human immunodeficiency virus associated nephropathy, Kidney Int Suppl, 35, S13

Pardo, 1984, Glomerular lesions in the acquired immunodeficiency syndrome, Ann Intern Med, 101, 429, 10.7326/0003-4819-101-4-429

D'Agati, 1989, Pathology of HIV-associated nephropathy: a detailed morphologic and comparative study, Kidney Int, 35, 1358, 10.1038/ki.1989.135

Rey, 1995, Immunopathological characteristics of in situ T-cell subpopulations in human immunodeficiency virus-associated nephropathy, Hum Pathol, 26, 408, 10.1016/0046-8177(95)90142-6

Bourgoignie, 1991, The nephropathology in human immunodeficiency virus (HIV-1) infection, Kidney Int Suppl, 35, S19

Rao, 1984, Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome, N Engl J Med, 310, 669, 10.1056/NEJM198403153101101

Thorner, 2008, Podocytes contribute to the formation of glomerular crescents, J Am Soc Nephrol, 19, 495, 10.1681/ASN.2006101115

Ronconi, 2009, Regeneration of glomerular podocytes by human renal progenitors, J Am Soc Nephrol, 20, 322, 10.1681/ASN.2008070709

Dijkman, 2006, Proliferating cells in HIV and pamidronate-associated collapsing focal segmental glomerulosclerosis are parietal epithelial cells, Kidney Int, 70, 338, 10.1038/sj.ki.5001574

Barisoni, 1999, The dysregulated podocyte phenotype: a novel concept in the pathogenesis of collapsing idiopathic focal segmental glomerulosclerosis and HIV-associated nephropathy, J Am Soc Nephrol, 10, 51, 10.1681/ASN.V10151

Kimmel, 2003, HIV-associated nephropathy: virologic issues related to renal sclerosis, Nephrol Dial Transplant, 18, vi59

Cohen, 1989, Demonstration of human immunodeficiency virus in renal epithelium in HIV-associated nephropathy, Mod Pathol, 2, 125

Kimmel, 1993, Viral DNA in microdissected renal biopsy tissue from HIV infected patients with nephrotic syndrome, Kidney Int, 43, 1347, 10.1038/ki.1993.189

Ray, 1998, Infection of human primary renal epithelial cells with HIV-1 from children with HIV-associated nephropathy, Kidney Int, 53, 1217, 10.1046/j.1523-1755.1998.00900.x

Bruggeman, 2000, Renal epithelium is a previously unrecognized site of HIV-1 infection, J Am Soc Nephrol, 11, 2079, 10.1681/ASN.V11112079

Marras, 2002, Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy, Nat Med, 8, 522, 10.1038/nm0502-522

Winston, 2001, Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection, N Engl J Med, 344, 1979, 10.1056/NEJM200106283442604

Bruggeman, 2009, Controversies in the pathogenesis of HIV-associated renal diseases, Nat Rev Nephrol, 5, 574, 10.1038/nrneph.2009.139

Cohen, 2008, Immune complex renal disease and human immunodeficiency virus infection, Semin Nephrol, 28, 535, 10.1016/j.semnephrol.2008.08.006

Haas, 2005, HIV-associated immune complex glomerulonephritis with “lupus-like” features: a clinicopathologic study of 14 cases, Kidney Int, 67, 1381, 10.1111/j.1523-1755.2005.00215.x

Kimmel, 1992, Brief report: idiotypic IgA nephropathy in patients with human immunodeficiency virus infection, N Engl J Med, 327, 702, 10.1056/NEJM199209033271006

Stokes, 1997, Immune complex glomerulonephritis in patients coinfected with human immunodeficiency virus and hepatitis C virus, Am J Kidney Dis, 29, 514, 10.1016/S0272-6386(97)90332-2

Gerntholtz, 2006, HIV-related nephropathy: a South African perspective, Kidney Int, 69, 1885, 10.1038/sj.ki.5000351

Han, 2006, A cross-sectional study of HIV-seropositive patients with varying degrees of proteinuria in South Africa, Kidney Int, 69, 2243, 10.1038/sj.ki.5000339

Wyatt, 2009, The spectrum of kidney disease in patients with AIDS in the era of antiretroviral therapy, Kidney Int, 75, 428, 10.1038/ki.2008.604

Gervasoni, 2002, Thrombotic microangiopathy in patients with acquired immunodeficiency syndrome before and during the era of introduction of highly active antiretroviral therapy, Clin Infect Dis, 35, 1534, 10.1086/344778

Fine, 2008, Thrombotic microangiopathy and other glomerular disorders in the HIV-infected patient, Semin Nephrol, 28, 545, 10.1016/j.semnephrol.2008.08.007

Cahen, 1989, Aetiology of membranous glomerulonephritis: a prospective study of 82 adult patients, Nephrol Dial Transplant, 4, 172, 10.1093/oxfordjournals.ndt.a091852

Kusner, 1991, Syphilis—a reversible cause of nephrotic syndrome in HIV infection, N Engl J Med, 324, 341, 10.1056/NEJM199101313240516

Cheng, 1999, Hepatitis C virus-associated glomerular disease in patients with human immunodeficiency virus coinfection, J Am Soc Nephrol, 10, 1566, 10.1681/ASN.V1071566

Naicker, 2010, Risk factors for the development of chronic kidney disease with HIV/AIDS, Clin Nephrol, 74, S51

Cozzi, 1992, Amyloidosis in association with human immunodeficiency virus infection, Clin Infect Dis, 14, 189, 10.1093/clinids/14.1.189

Tourret, 2006, Outcome and prognosis factors in HIV-infected hemodialysis patients, Clin J Am Soc Nephrol, 1, 1241, 10.2215/CJN.02211205

Khanna, 2005, Survival experience of peritoneal dialysis patients with human immunodeficiency virus: a 17-year retrospective study, Adv Perit Dial, 21, 159

Atta, 2007, Survival during renal replacement therapy among African Americans infected with HIV type 1 in urban Baltimore, Maryland, Clin Infect Dis, 45, 1625, 10.1086/523728

Macrae, 2005, Improved survival in HIV-infected African-Americans with ESRD, Clin Nephrol, 64, 124, 10.5414/CNP64124

Ahuja, 2002, Changing trends in the survival of dialysis patients with human immunodeficiency virus in the United States, J Am Soc Nephrol, 13, 1889, 10.1097/01.ASN.0000019773.43765.BF

Stock, 2010, Outcomes of kidney transplantation in HIV-infected recipients, N Engl J Med, 363, 2004, 10.1056/NEJMoa1001197

Ibrahim, 2010, Immunodeficiency and renal impairment are risk factors for HIV-associated acute renal failure, AIDS, 24, 2239, 10.1097/QAD.0b013e32833c85d6

Franceschini, 2005, Incidence and etiology of acute renal failure among ambulatory HIV-infected patients, Kidney Int, 67, 1526, 10.1111/j.1523-1755.2005.00232.x

Wyatt, 2006, Acute renal failure in hospitalized patients with HIV: risk factors and impact on in-hospital mortality, AIDS, 20, 561, 10.1097/01.aids.0000210610.52836.07

Hillege, 2002, Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population, Circulation, 106, 1777, 10.1161/01.CIR.0000031732.78052.81

Vupputuri, 2008, Microalbuminuria, peripheral artery disease, and cognitive function, Kidney Int, 73, 341, 10.1038/sj.ki.5002672

Jassal, 2010, A prospective study of albuminuria and cognitive function in older adults: the Rancho Bernardo study, Am J Epidemiol, 171, 277, 10.1093/aje/kwp426

Joosten, 2011, Association of cognitive function with albuminuria and eGFR in the general population, Clin J Am Soc Nephrol, 6, 1400, 10.2215/CJN.05530610

Barzilay, 2011, Albuminuria and decline in cognitive function: the ONTARGET/TRANSCEND studies, Arch Intern Med, 171, 142, 10.1001/archinternmed.2010.502

George, 2010, Kidney function and the risk of cardiovascular events in HIV-1-infected patients, AIDS, 24, 387, 10.1097/QAD.0b013e3283359253

Becker, 2009, Vascular risk factors, HIV serostatus, and cognitive dysfunction in gay and bisexual men, Neurology, 73, 1292, 10.1212/WNL.0b013e3181bd10e7

Alonso, 2011, Chronic kidney disease is associated with the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities (ARIC) study, Circulation, 123, 2946, 10.1161/CIRCULATIONAHA.111.020982

Mulenga, 2008, Baseline renal insufficiency and risk of death among HIV-infected adults on antiretroviral therapy in Lusaka, Zambia, AIDS, 22, 1821, 10.1097/QAD.0b013e328307a051

Szczech, 2004, Association between renal disease and outcomes among HIV-infected women receiving or not receiving antiretroviral therapy, Clin Infect Dis, 39, 1199, 10.1086/424013

Estrella, 2010, The impact of kidney function at highly active antiretroviral therapy initiation on mortality in HIV-infected women, J Acquir Immune Defic Syndr, 55, 217, 10.1097/QAI.0b013e3181e674f4

Mayor, 2010, The morbidity and mortality associated with kidney disease in an HIV-infected cohort in Puerto Rico, Ethn Dis, 20

Buskin, 2009, Trends in nephropathy among HIV-infected patients, J Natl Med Assoc, 101, 1205, 10.1016/S0027-9684(15)31131-7

Wyatt, 2010, Microalbuminuria is associated with all-cause and AIDS mortality in women with HIV infection, J Acquir Immune Defic Syndr, 55, 73, 10.1097/QAI.0b013e3181cc1070

Choi, 2007, Low rates of antiretroviral therapy among HIV-infected patients with chronic kidney disease, Clin Infect Dis, 45, 1633, 10.1086/523729

Department of Health and Human Services, 2013, . Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents:

Thompson, 2012, Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel, JAMA, 308, 387, 10.1001/jama.2012.7961

Herlitz, 2010, Tenofovir nephrotoxicity: acute tubular necrosis with distinctive clinical, pathological, and mitochondrial abnormalities, Kidney Int, 78, 1171, 10.1038/ki.2010.318

Karras, 2003, Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus, Clin Infect Dis, 36, 1070, 10.1086/368314

Zimmermann, 2006, Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions, Clin Infect Dis, 42, 283, 10.1086/499048

Kiser, 2008, Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients, J Acquir Immune Defic Syndr, 47, 298, 10.1097/QAI.0b013e31815e7478

Kohler, 2011, Tenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transporters, Lab Invest, 91, 852, 10.1038/labinvest.2011.48

Rodriguez-Novoa, 2009, Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study, Clin Infect Dis, 48, e108, 10.1086/598507

Nishijima, 2012, Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study, Clin Infect Dis, 55, 1558, 10.1093/cid/cis772

Nelson, 2007, The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years, AIDS, 21, 1273, 10.1097/QAD.0b013e3280b07b33

Post, 2010, Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study, J Acquir Immune Defic Syndr, 55, 49, 10.1097/QAI.0b013e3181dd911e

Vrouenraets, 2011, Persistent decline in estimated but not measured glomerular filtration rate on tenofovir may reflect tubular rather than glomerular toxicity, AIDS, 25, 2149, 10.1097/QAD.0b013e32834bba87

Kinai, 2009, Progressive renal tubular dysfunction associated with long-term use of tenofovir DF, AIDS Res Hum Retroviruses, 25, 387, 10.1089/aid.2008.0202

Maggi, 2012, Early markers of tubular dysfunction in antiretroviral-experienced HIV-infected patients treated with tenofovir versus abacavir, AIDS Patient Care STDS, 26, 5, 10.1089/apc.2011.0185

Dauchy, 2011, Increased risk of abnormal proximal renal tubular function with HIV infection and antiretroviral therapy, Kidney Int, 80, 302, 10.1038/ki.2011.124

Calza, 2011, Tenofovir-induced renal toxicity in 324 HIV-infected, antiretroviral-naive patients, Scand J Infect Dis, 43, 656, 10.3109/00365548.2011.572906

Labarga, 2009, Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir, AIDS, 23, 689, 10.1097/QAD.0b013e3283262a64

Judd, 2010, Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study, AIDS, 24, 525, 10.1097/QAD.0b013e3283333680

Horberg, 2010, Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients, J Acquir Immune Defic Syndr, 53, 62, 10.1097/QAI.0b013e3181be6be2

Papaleo, 2007, Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir, Pediatr Infect Dis J, 26, 949, 10.1097/INF.0b013e3181256570

Hall, 2009, Subclinical tubular injury in HIV-infected individuals on antiretroviral therapy: a cross-sectional analysis, Am J Kidney Dis, 54, 1034, 10.1053/j.ajkd.2009.07.012

Gatanaga, 2006, Urinary beta (2)-microglobulin as a possible sensitive marker for renal injury caused by tenofovir disoproxil fumarate, AIDS Res Hum Retroviruses, 22, 744, 10.1089/aid.2006.22.744

Vigano, 2007, Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study, Clin Drug Investig, 27, 573, 10.2165/00044011-200727080-00006

Fux, 2007, Tenofovir use is associated with a reduction in calculated glomerular filtration rates in the swiss HIV Cohort Study, Antivir Ther, 12, 1165, 10.1177/135965350701200812

Day, 2005, Serum hypophosphatemia in tenofovir disoproxil fumarate recipients is multifactorial in origin, questioning the utility of its monitoring in clinical practice, J Acquir Immune Defic Syndr, 38, 301

Buchacz, 2006, Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy, HIV Med, 7, 451, 10.1111/j.1468-1293.2006.00407.x

Samarawickrama, 2012, Simultaneous measurement of urinary albumin and total protein may facilitate decision-making in HIV-infected patients with proteinuria, HIV Med, 13, 526, 10.1111/j.1468-1293.2012.01003.x

Gallant, 2008, The 3-year renal safety of a tenofovir disoproxil fumarate vs. a thymidine analogue-containing regimen in antiretroviral-naive patients, AIDS, 22, 2155, 10.1097/QAD.0b013e3283112b8e

Sax, 2011, Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results, J Infect Dis, 204, 1191, 10.1093/infdis/jir505

Daar, 2011, Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1: a randomized trial, Ann Intern Med, 154, 445, 10.7326/0003-4819-154-7-201104050-00316

Cooper, 2010, Systematic review and meta-analysis: renal safety of tenofovir disoproxil fumarate in HIV-infected patients, Clin Infect Dis, 51, 496, 10.1086/655681

Flandre, 2011, Risk factors of chronic kidney disease in HIV-infected patients, Clin J Am Soc Nephrol, 6, 1700, 10.2215/CJN.09191010

Scherzer, 2012, Association of tenofovir exposure with kidney disease risk in HIV infection, AIDS, 26, 867, 10.1097/QAD.0b013e328351f68f

Crane, 2007, Amprenavir and didanosine are associated with declining kidney function among patients receiving tenofovir, AIDS, 21, 1431, 10.1097/QAD.0b013e3281fc9320

Gallant, 2009, Renal function with use of a tenofovir-containing initial antiretroviral regimen, AIDS, 23, 1971, 10.1097/QAD.0b013e32832c96e9

Kiser, 2008, The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients, Clin Pharmacol Ther, 83, 265, 10.1038/sj.clpt.6100269

Goicoechea, 2008, Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy, J Infect Dis, 197, 102, 10.1086/524061

Wever, 2010, Incomplete reversibility of tenofovir-related renal toxicity in HIV-infected men, J Acquir Immune Defic Syndr, 55, 78, 10.1097/QAI.0b013e3181d05579

Voigt, 2002, First-line ritonavir/indinavir 100/800 mg twice daily plus nucleoside reverse transcriptase inhibitors in a German multicentre study: 48-week results, HIV Med, 3, 277, 10.1046/j.1468-1293.2002.00123.x

van Rossum, 2002, Persistent sterile leukocyturia is associated with impaired renal function in human immunodeficiency virus type 1-infected children treated with indinavir, Pediatrics, 110, e19, 10.1542/peds.110.2.e19

Kopp, 1997, Crystalluria and urinary tract abnormalities associated with indinavir, Ann Intern Med, 127, 119, 10.7326/0003-4819-127-2-199707150-00004

Campbell, 2009, Spectrum of chronic kidney disease in HIV-infected patients, HIV Med, 10, 329, 10.1111/j.1468-1293.2008.00691.x

Hamada, 2012, High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy, Clin Infect Dis, 55, 1262, 10.1093/cid/cis621

Pacanowski, 2006, Atazanavir urinary stones in an HIV-infected patient, AIDS, 20, 2131, 10.1097/01.aids.0000247571.88256.90

Chan-Tack, 2007, Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System, AIDS, 21, 1215, 10.1097/QAD.0b013e32813aee35

Ryom, 2013, Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study, J Infect Dis, 207, 1359, 10.1093/infdis/jit043

German, 2012, Effect of cobicistat on glomerular filtration rate in subjects with normal and impaired renal function, J Acquir Immune Defic Syndr, 61, 32, 10.1097/QAI.0b013e3182645648

Lepist, 2012, Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro, Antimicrob Agents Chemother, 56, 5409, 10.1128/AAC.01089-12

DeJesus, 2012, Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial, Lancet, 379, 2429, 10.1016/S0140-6736(12)60918-0

Molina, 2011, Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial, Lancet, 378, 238, 10.1016/S0140-6736(11)60936-7

Walmsley, 2013, Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection, N Engl J Med, 369, 1807, 10.1056/NEJMoa1215541

Andreev, 1999, A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible?, J Intern Med, 246, 247, 10.1046/j.1365-2796.1999.00515.x

Kobayashi, 2011, In vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor, Antimicrob Agents Chemother, 55, 813, 10.1128/AAC.01209-10

Swanson, 2002, Impact of HIV seropositivity on graft and patient survival after cadaveric renal transplantation in the United States in the pre highly active antiretroviral therapy (HAART) era: an historical cohort analysis of the United States Renal Data System, Transpl Infect Dis, 4, 144, 10.1034/j.1399-3062.2002.01009.x

Wolfe, 1999, Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant, N Engl J Med, 341, 1725, 10.1056/NEJM199912023412303

Trullas, 2010, Dialysis and renal transplantation in HIV-infected patients: a European survey, J Acquir Immune Defic Syndr, 55, 582, 10.1097/QAI.0b013e3181efbe59

Abbott, 2004, Human immunodeficiency virus infection and kidney transplantation in the era of highly active antiretroviral therapy and modern immunosuppression, J Am Soc Nephrol, 15, 1633, 10.1097/01.ASN.0000127987.19470.3A

Qiu, 2006, HIV-positive renal recipients can achieve survival rates similar to those of HIV-negative patients, Transplantation, 81, 1658, 10.1097/01.tp.0000226074.97314.e0

Kuo, 2001, Transplantation in the HIV+ patient, Am J Transplant, 1, 13, 10.1034/j.1600-6143.2001.010104.x

Stock, 2001, Solid organ transplantation in HIV-positive patients, Transplant Proc, 33, 3646, 10.1016/S0041-1345(01)02569-6

Roland, 2003, Review of solid-organ transplantation in HIV-infected patients, Transplantation, 75, 425, 10.1097/01.TP.0000046943.35335.18

Toso, 2003, Kidney-pancreas transplantation in a long-term non-progressor HIV-infected recipient, Am J Transplant, 3, 631, 10.1034/j.1600-6143.2003.00119.x

Stock, 2003, Kidney and liver transplantation in human immunodeficiency virus-infected patients: a pilot safety and efficacy study, Transplantation, 76, 370, 10.1097/01.TP.0000075973.73064.A6

Kumar, 2005, Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients, Kidney Int, 67, 1622, 10.1111/j.1523-1755.2005.00245.x

Roland, 2008, HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes, Am J Transplant, 8, 355, 10.1111/j.1600-6143.2007.02061.x

Gruber, 2008, Preliminary experience with renal transplantation in HIV+ recipients: low acute rejection and infection rates, Transplantation, 86, 269, 10.1097/TP.0b013e318177884e

Muller, 2006, HIV and solid organ transplantation: the Swiss experience, Swiss Med Wkly, 136, 194

Ballarin, 2008, Combined liver-kidney transplantation in an HIV-HCV-coinfected patient with haemophilia, AIDS, 22, 2047, 10.1097/QAD.0b013e32830f4c8d

Billault, 2009, Kidney transplantation in HIV-positive patients: report of our first 7 cases, Transplant Proc, 41, 3301, 10.1016/j.transproceed.2009.08.039

Touzot, 2010, Renal transplantation in HIV-infected patients: the Paris experience, Am J Transplant, 10, 2263, 10.1111/j.1600-6143.2010.03258.x

Trullas, 2011, Renal transplantation in HIV-infected patients: 2010 update, Kidney Int, 79, 825, 10.1038/ki.2010.545

Mugyenyi, 2010, Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial, Lancet, 375, 123, 10.1016/S0140-6736(09)62067-5

Estrella, 2006, HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients, Clin Infect Dis, 43, 377, 10.1086/505497

Cosgrove, 2002, Observations on HIV-associated renal disease in the era of highly active antiretroviral therapy, Am J Med Sci, 323, 102, 10.1097/00000441-200202000-00009

Szczech, 2002, Protease inhibitors are associated with a slowed progression of HIV-related renal diseases, Clin Nephrol, 57, 336, 10.5414/CNP57336

Wei, 2003, Long-term renal survival in HIV-associated nephropathy with angiotensin-converting enzyme inhibition, Kidney Int, 64, 1462, 10.1046/j.1523-1755.2003.00230.x

Atta, 2006, Antiretroviral therapy in the treatment of HIV-associated nephropathy, Nephrol Dial Transplant, 21, 2809, 10.1093/ndt/gfl337

Kimmel, 1996, Captopril and renal survival in patients with human immunodeficiency virus nephropathy, Am J Kidney Dis, 28, 202, 10.1016/S0272-6386(96)90302-9

Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children, 2014, Guidelines for the use of antiretroviral agents in pediatric HIV infection,

2010, Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996–2006: collaborative analysis of 13 HIV cohort studies, Clin Infect Dis, 50, 1387, 10.1086/652283

Levey, 2006, Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate, Ann Intern Med, 145, 247, 10.7326/0003-4819-145-4-200608150-00004

Grubb, 2010, First certified reference material for cystatin C in human serum ERM-DA471/IFCC, Clin Chem Lab Med, 48, 1619, 10.1515/CCLM.2010.318

Matzke, 2011, Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO), Kidney Int, 80, 1122, 10.1038/ki.2011.322

Brenner, 2001, Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N Engl J Med, 345, 861, 10.1056/NEJMoa011161

Tobe, 2011, Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies, Circulation, 123, 1098, 10.1161/CIRCULATIONAHA.110.964171

Lewis, 2001, Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes, N Engl J Med, 345, 851, 10.1056/NEJMoa011303

Fink, 2012, Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline, Ann Intern Med, 156, 570, 10.7326/0003-4819-156-8-201204170-00008

2007, KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease, Am J Kidney Dis, 49, S12, 10.1053/j.ajkd.2006.12.005

Ahuja, 1999, Is the prevalence of HIV-associated nephropathy decreasing?, Am J Nephrol, 19, 655, 10.1159/000013537

Izzedine, 2009, Kidney diseases in HIV/HCV-co-infected patients, AIDS, 23, 1219, 10.1097/QAD.0b013e32832ac36a

Ha, 2009, Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil, Hepatology, 50, 727, 10.1002/hep.23044

Tamori, 2010, Add-on combination therapy with adefovir dipivoxil induces renal impairment in patients with lamivudine-refractory hepatitis B virus, J Viral Hepat, 17, 123, 10.1111/j.1365-2893.2009.01160.x

Markowitz, 2010, Treatment with IFN-{alpha}, -{beta}, or -{gamma} is associated with collapsing focal segmental glomerulosclerosis, Clin J Am Soc Nephrol, 5, 607, 10.2215/CJN.07311009

Hunsicker, 1997, Predictors of the progression of renal disease in the Modification of Diet in Renal Disease Study, Kidney Int, 51, 1908, 10.1038/ki.1997.260

Fuiano, 2000, Current indications for renal biopsy: a questionnaire-based survey, Am J Kidney Dis, 35, 448, 10.1016/S0272-6386(00)70197-1

Levey, 2011, The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report, Kidney Int, 80, 17, 10.1038/ki.2010.483

D'Agati, 1998, Renal pathology of human immunodeficiency virus infection, Semin Nephrol, 18, 406

Atta, 2005, Nephrotic range proteinuria and CD4 count as noninvasive indicators of HIV-associated nephropathy, Am J Med, 118, 1288, 10.1016/j.amjmed.2005.05.027

Atta, 2004, Sonography as a predictor of human immunodeficiency virus-associated nephropathy, J Ultrasound Med, 23, 603, 10.7863/jum.2004.23.5.603

Tabatabai, 2009, Predictors of complication after percutaneous ultrasound-guided kidney biopsy in HIV-infected individuals: possible role of hepatitis C and HIV co-infection, Clin J Am Soc Nephrol, 4, 1766, 10.2215/CJN.03880609

Hergesell, 1998, Safety of ultrasound-guided percutaneous renal biopsy-retrospective analysis of 1090 consecutive cases, Nephrol Dial Transplant, 13, 975, 10.1093/ndt/13.4.975

Whittier, 2004, Timing of complications in percutaneous renal biopsy, J Am Soc Nephrol, 15, 142, 10.1097/01.ASN.0000102472.37947.14

Manno, 2004, Predictors of bleeding complications in percutaneous ultrasound-guided renal biopsy, Kidney Int, 66, 1570, 10.1111/j.1523-1755.2004.00922.x

Spivak, 1989, Serum immunoreactive erythropoietin in HIV-infected patients, JAMA, 261, 3104, 10.1001/jama.1989.03420210052015

Ifudu, 1997, Severity of AIDS and the response to EPO in uremia, Am J Kidney Dis, 30, 28, 10.1016/S0272-6386(97)90561-8

Solomon, 2010, Erythropoietic response and outcomes in kidney disease and type 2 diabetes, N Engl J Med, 363, 1146, 10.1056/NEJMoa1005109

2006, KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease, Am J Kidney Dis, 47, S11

2003, K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease, Am J Kidney Dis, 42, S1, 10.1016/S0272-6386(03)00905-3

2009, KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD), Kidney Int Suppl, 76, 132

Black, 2010, Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis, Health Technol Assess, 14, 1, 10.3310/hta14210

Ahuja, 2003, Is dialysis modality a factor in survival of patients with ESRD and HIV-associated nephropathy?, Am J Kidney Dis, 41, 1060, 10.1016/S0272-6386(03)00204-X

Mitchell, 2006, Catheter-related bacteraemia in haemodialysis patients with HIV infection, Nephrol Dial Transplant, 21, 3185, 10.1093/ndt/gfl425

Brock, 1992, The influence of human immunodeficiency virus infection and intravenous drug abuse on complications of hemodialysis access surgery, J Vasc Surg, 16, 904, 10.1016/0741-5214(92)90053-B

Mitchell, 2007, Arteriovenous access outcomes in haemodialysis patients with HIV infection, Nephrol Dial Transplant, 22, 465, 10.1093/ndt/gfl629

Mendelssohn, 2011, Suboptimal initiation of dialysis with and without early referral to a nephrologist, Nephrol Dial Transplant, 26, 2959, 10.1093/ndt/gfq843

Hoggard, 2008, Guidelines for venous access in patients with chronic kidney disease. A position statement from the American Society of Diagnostic and Interventional Nephrology, Clinical Practice Committee and the Association for Vascular Access, Semin Dial, 21, 186, 10.1111/j.1525-139X.2008.00421.x

Abbott, 2003, HIVAN and medication use in chronic dialysis patients in the United States: analysis of the USRDS DMMS Wave 2 study, BMC Nephrol, 4, 5, 10.1186/1471-2369-4-5

Rodriguez, 2003, Determinants of survival among HIV-infected chronic dialysis patients, J Am Soc Nephrol, 14, 1307, 10.1097/01.ASN.0000062963.56513.28

Szczech, 2003, The clinical characteristics and antiretroviral dosing patterns of HIV-infected patients receiving dialysis, Kidney Int, 63, 2295, 10.1046/j.1523-1755.2003.00031.x

Tourret, 2007, Antiretroviral drug dosing errors in HIV-infected patients undergoing hemodialysis, Clin Infect Dis, 45, 779, 10.1086/521168

Rastegar, 2006, Antiretroviral medication errors among hospitalized patients with HIV infection, Clin Infect Dis, 43, 933, 10.1086/507538

Willig, 2007, Nucleoside reverse-transcriptase inhibitor dosing errors in an outpatient HIV clinic in the electronic medical record era, Clin Infect Dis, 45, 658, 10.1086/520653

Gupta, 2008, The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis, AIDS, 22, 1919, 10.1097/QAD.0b013e32830e011f

Post, 2008, Predictors of renal outcome in HIV-associated nephropathy, Clin Infect Dis, 46, 1282, 10.1086/529385

Becker, 2004, HIV-associated thrombotic microangiopathy in the era of highly active antiretroviral therapy: an observational study, Clin Infect Dis, 39, S267, 10.1086/422363

Miller, 2005, Thrombotic thrombocytopaenic purpura in HIV-infected patients, Int J STD AIDS, 16, 538, 10.1258/0956462054679241

Choi, 2009, HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy, AIDS, 23, 2143, 10.1097/QAD.0b013e3283313c91

El-Sadr, 2006, CD4+ count-guided interruption of antiretroviral treatment, N Engl J Med, 355, 2283, 10.1056/NEJMoa062360

Reid, 2008, Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy, Clin Infect Dis, 46, 1271, 10.1086/533468

Peters, 2008, Antiretroviral therapy improves renal function among HIV-infected Ugandans, Kidney Int, 74, 925, 10.1038/ki.2008.305

El-Sadr, 2008, Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial, Ann Intern Med, 149, 289, 10.7326/0003-4819-149-5-200809020-00003

Young, 2009, Renal function in patients with preexisting renal disease receiving tenofovir-containing highly active antiretroviral therapy in the HIV outpatient study, AIDS Patient Care STDS, 23, 589, 10.1089/apc.2008.0232

Brennan, 2011, Relationship between renal dysfunction, nephrotoxicity and death among HIV adults on tenofovir, AIDS, 25, 1603, 10.1097/QAD.0b013e32834957da

Bygrave, 2011, Renal safety of a tenofovir-containing first line regimen: experience from an antiretroviral cohort in rural Lesotho, PLoS One, 6, e17609, 10.1371/journal.pone.0017609

Chi, 2010, Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia, J Acquir Immune Defic Syndr, 54, 63, 10.1097/QAI.0b013e3181c6c65c

De Beaudrap, 2010, Changes in the renal function after tenofovir-containing antiretroviral therapy initiation in a Senegalese cohort (ANRS 1215), AIDS Res Hum Retroviruses, 26, 1221, 10.1089/aid.2009.0261

Mulenga, 2014, Effect of baseline renal function on tenofovir-containing antiretroviral therapy outcomes in Zambia, Clin Infect Dis, 58, 1473, 10.1093/cid/ciu117

Smith, 2012, The value of simultaneous measurements of urinary albumin and total protein in proteinuric patients, Nephrol Dial Transplant, 27, 1534, 10.1093/ndt/gfr708

Mallal, 2008, HLA-B*5701 screening for hypersensitivity to abacavir, N Engl J Med, 358, 568, 10.1056/NEJMoa0706135

Sax, 2009, Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy, N Engl J Med, 361, 2230, 10.1056/NEJMoa0906768

2008, Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients, AIDS, 22, F17, 10.1097/QAD.0b013e32830fe35e

Choi, 2011, Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons, AIDS, 25, 1289, 10.1097/QAD.0b013e328347fa16

Obel, 2010, Abacavir and risk of myocardial infarction in HIV-infected patients on highly active antiretroviral therapy: a population-based nationwide cohort study, HIV Med, 11, 130, 10.1111/j.1468-1293.2009.00751.x

Sabin, 2008, Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration, Lancet, 371, 1417, 10.1016/S0140-6736(08)60423-7

Bedimo, 2011, Abacavir use and risk of acute myocardial infarction and cerebrovascular events in the highly active antiretroviral therapy era, Clin Infect Dis, 53, 84, 10.1093/cid/cir269

Cruciani, 2011, Abacavir use and cardiovascular disease events: a meta-analysis of published and unpublished data, AIDS, 25, 1993, 10.1097/QAD.0b013e328349c6ee

Ribaudo, 2011, No risk of myocardial infarction associated with initial antiretroviral treatment containing abacavir: short and long-term results from ACTG A5001/ALLRT, Clin Infect Dis, 52, 929, 10.1093/cid/ciq244

Delfraissy, 2008, Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients, AIDS, 22, 385, 10.1097/QAD.0b013e3282f3f16d

Clumeck, 2011, 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline, J Antimicrob Chemother, 66, 1878, 10.1093/jac/dkr199

Haubrich, 2009, Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment, AIDS, 23, 1109, 10.1097/QAD.0b013e32832b4377

Riddler, 2008, Class-sparing regimens for initial treatment of HIV-1 infection, N Engl J Med, 358, 2095, 10.1056/NEJMoa074609

Nozza, 2011, Durability and safety of a novel salvage therapy in R5-tropic HIV-infected patients: maraviroc, raltegravir, etravirine, J Acquir Immune Defic Syndr, 56, e113, 10.1097/QAI.0b013e31820a9ae4

Mills, 2013, Maraviroc once-daily nucleoside analog-sparing regimen in treatment-naive patients: randomized, open-label pilot study, J Acquir Immune Defic Syndr, 62, 164, 10.1097/QAI.0b013e31827b51b5

Kozal, 2012, A nucleoside- and ritonavir-sparing regimen containing atazanavir plus raltegravir in antiretroviral treatment-naive HIV-infected patients: SPARTAN study results, HIV Clin Trials, 13, 119, 10.1310/hct1303-119

Reynes, 2011, Examination of noninferiority, safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naive subjects: the progress study, 48-week results, HIV Clin Trials, 12, 255, 10.1310/hct1205-255

Taiwo, 2011, Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262), AIDS, 25, 2113, 10.1097/QAD.0b013e32834bbaa9

Raffi, First-line RAL + DRV/r is non-inferior to TDF/FTC + DRV/r

Newman, 2005, Systematic review on urine albumin testing for early detection of diabetic complications, Health Technol Assess, 9, 10.3310/hta9300

Hirst, 2012, The impact of renin-angiotensin-aldosterone system inhibitors on type 1 and type 2 diabetic patients with and without early diabetic nephropathy, Kidney Int, 81, 674, 10.1038/ki.2011.413

Lewis, 1993, The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group, N Engl J Med, 329, 1456, 10.1056/NEJM199311113292004

Parving, 2001, The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes, N Engl J Med, 345, 870, 10.1056/NEJMoa011489

Strippoli, 2006, Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease, Cochrane Database Syst Rev, 4

1997, Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia), Lancet, 349, 1857, 10.1016/S0140-6736(96)11445-8

Ruggenenti, 1998, Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy, Lancet, 352, 1252, 10.1016/S0140-6736(98)04433-X

Ruggenenti, 1999, Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria, Lancet, 354, 359, 10.1016/S0140-6736(98)10363-X

Wright, 2002, Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial, JAMA, 288, 2421, 10.1001/jama.288.19.2421

Kent, 2007, Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease, J Am Soc Nephrol, 18, 1959, 10.1681/ASN.2006101081

Ruggenenti, 2005, Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial, Lancet, 365, 939, 10.1016/S0140-6736(05)71082-5

Kunz, 2008, Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease, Ann Intern Med, 148, 30, 10.7326/0003-4819-148-1-200801010-00190

Yusuf, 2008, Telmisartan, ramipril, or both in patients at high risk for vascular events, N Engl J Med, 358, 1547, 10.1056/NEJMoa0801317

Mann, 2008, Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial, Lancet, 372, 547, 10.1016/S0140-6736(08)61236-2

Maione, 2011, Angiotensin-converting enzyme inhibitors, angiotensin receptor blockers and combined therapy in patients with micro- and macroalbuminuria and other cardiovascular risk factors: a systematic review of randomized controlled trials, Nephrol Dial Transplant, 26, 2827, 10.1093/ndt/gfq792

Stone, 2014, 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, Circulation, 129, S1, 10.1161/01.cir.0000437738.63853.7a

Weiner, 2004, Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies, J Am Soc Nephrol, 15, 1307, 10.1097/01.ASN.0000123691.46138.E2

Upadhyay, 2012, Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis, Ann Intern Med, 157, 251, 10.7326/0003-4819-157-4-201208210-00005

Palmer, 2012, Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis, Ann Intern Med, 157, 263, 10.7326/0003-4819-157-4-201208210-00007

Ridker, 2010, Efficacy of rosuvastatin among men and women with moderate chronic kidney disease and elevated high-sensitivity C-reactive protein: a secondary analysis from the JUPITER (Justification for the Use of Statins in Prevention—an Intervention Trial Evaluating Rosuvastatin) trial, J Am Coll Cardiol, 55, 1266, 10.1016/j.jacc.2010.01.020

Baigent, 2011, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial, Lancet, 377, 2181, 10.1016/S0140-6736(11)60739-3

Colhoun, 2009, Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS), Am J Kidney Dis, 54, 810, 10.1053/j.ajkd.2009.03.022

Fellstrom, 2009, Rosuvastatin and cardiovascular events in patients undergoing hemodialysis, N Engl J Med, 360, 1395, 10.1056/NEJMoa0810177

Wanner, 2005, Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis, N Engl J Med, 353, 238, 10.1056/NEJMoa043545

Wolff, 2009, Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force, Ann Intern Med, 150, 405, 10.7326/0003-4819-150-6-200903170-00009

US Preventive Services Task Force, 2009, Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement, Ann Intern Med, 150, 396, 10.7326/0003-4819-150-6-200903170-00008

Burkholder, 2012, Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients, Clin Infect Dis, 55, 1550, 10.1093/cid/cis752

Jardine, 2010, Aspirin is beneficial in hypertensive patients with chronic kidney disease: a post-hoc subgroup analysis of a randomized controlled trial, J Am Coll Cardiol, 56, 956, 10.1016/j.jacc.2010.02.068

Baigent, 2005, First United Kingdom Heart and Renal Protection (UK-HARP-I) study: biochemical efficacy and safety of simvastatin and safety of low-dose aspirin in chronic kidney disease, Am J Kidney Dis, 45, 473, 10.1053/j.ajkd.2004.11.015

Baigent, 2009, Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials, Lancet, 373, 1849, 10.1016/S0140-6736(09)60503-1

Pignone, 2010, Aspirin for primary prevention of cardiovascular events in people with diabetes, J Am Coll Cardiol, 55, 2878, 10.1016/j.jacc.2010.04.003

Cooper, 2006, Major congenital malformations after first-trimester exposure to ACE inhibitors, N Engl J Med, 354, 2443, 10.1056/NEJMoa055202

Sekine, 2009, Children's toxicology from bench to bed—drug-induced renal injury (1): the toxic effects of ARB/ACEI on fetal kidney development, J Toxicol Sci, 34, SP245, 10.2131/jts.34.SP245

Lopez-Sendon, 2004, Expert consensus document on angiotensin converting enzyme inhibitors in cardiovascular disease. The Task Force on ACE-inhibitors of the European Society of Cardiology, Eur Heart J, 25, 1454, 10.1016/j.ehj.2004.06.003

Aberg, 2014, Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV Medicine Association of the Infectious Diseases Society of America, Clin Infect Dis, 58, e1, 10.1093/cid/cit665

Upadhyay, 2011, Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier, Ann Intern Med, 154, 541, 10.7326/0003-4819-154-8-201104190-00335

Peterson, 1995, Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study, Ann Intern Med, 123, 754, 10.7326/0003-4819-123-10-199511150-00003

Eustace, 2000, Cohort study of the treatment of severe HIV-associated nephropathy with corticosteroids, Kidney Int, 58, 1253, 10.1046/j.1523-1755.2000.00280.x

Laradi, 1998, HIV-associated nephropathy: outcome and prognosis factors. Groupe d’ Etudes Nephrologiques d'Ile de France, J Am Soc Nephrol, 9, 2327, 10.1681/ASN.V9122327

Smith, 1996, Prednisone improves renal function and proteinuria in human immunodeficiency virus-associated nephropathy, Am J Med, 101, 41, 10.1016/S0002-9343(96)00065-4

Briggs, 1996, Clinicopathologic correlates of prednisone treatment of human immunodeficiency virus-associated nephropathy, Am J Kidney Dis, 28, 618, 10.1016/S0272-6386(96)90477-1

Smith, 1994, Effect of corticosteroid therapy on human immunodeficiency virus-associated nephropathy, Am J Med, 97, 145, 10.1016/0002-9343(94)90024-8

Scribner, 2000, Osteonecrosis in HIV: a case-control study, J Acquir Immune Defic Syndr, 25, 19, 10.1097/00126334-200009010-00003

Miller, 2002, High prevalence of osteonecrosis of the femoral head in HIV-infected adults, Ann Intern Med, 137, 17, 10.7326/0003-4819-137-1-200207020-00008

Glesby, 2001, Osteonecrosis in patients infected with human immunodeficiency virus: a case-control study, J Infect Dis, 184, 519, 10.1086/322779

1992, 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults, MMWR Recomm Rep, 41, 1

Miro, 2005, GESIDA/GESITRA-SEIMC, PNS and ONT consensus document on solid organ transplant (SOT) in HIV-infected patients in Spain (March, 2005), Enferm Infecc Microbiol Clin, 23, 353

Di Benedetto, 2008, Human immunodeficiency virus and liver transplantation: our point of view, Transplant Proc, 40, 1965, 10.1016/j.transproceed.2008.05.067

Bhagani, 2006, Guidelines for kidney transplantation in patients with HIV disease, HIV Med, 7, 133, 10.1111/j.1468-1293.2006.00367.x

Blumberg, 2009, Solid organ transplantation in the HIV-infected patient, Am J Transplant, 9, S131, 10.1111/j.1600-6143.2009.02903.x

Mazuecos, 2006, Renal transplantation in HIV-infected patients in Spain, Nefrologia, 26, 113

Grossi, 2006, Liver transplantation in HIV-infected individuals: results of the Italian national program, Transplantation, 82, 446, 10.1097/00007890-200607152-01125

Marconi, 2011, Cumulative viral load and virologic decay patterns after antiretroviral therapy in HIV-infected subjects influence CD4 recovery and AIDS, PLoS One, 6, e17956, 10.1371/journal.pone.0017956

Lucas, 2003, Survival in an urban HIV-1 clinic in the era of highly active antiretroviral therapy: a 5-year cohort study, J Acquir Immune Defic Syndr, 33, 321, 10.1097/00126334-200307010-00005

Alter, 2006, Epidemiology of viral hepatitis and HIV co-infection, J Hepatol, 44, S6, 10.1016/j.jhep.2005.11.004

Hanafusa, 1998, Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years, Transplantation, 66, 471, 10.1097/00007890-199808270-00010

Lesens, 1999, Hepatitis C virus is related to progressive liver disease in human immunodeficiency virus-positive hemophiliacs and should be treated as an opportunistic infection, J Infect Dis, 179, 1254, 10.1086/314720

Mohsen, 2003, Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients, Gut, 52, 1035, 10.1136/gut.52.7.1035

Smit, 2008, Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study, J Acquir Immune Defic Syndr, 47, 221, 10.1097/QAI.0b013e31815d2f59

Dore, 2011, Future of hepatitis C therapy: development of direct-acting antivirals, Curr Opin HIV AIDS, 6, 508, 10.1097/COH.0b013e32834b87f8

Sulkowski, 2014, Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection, N Engl J Med, 370, 211, 10.1056/NEJMoa1306218

Kowdley, 2014, Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1, N Engl J Med, 370, 222, 10.1056/NEJMoa1306227

Jain, 2003, Effect of coadministered lopinavir and ritonavir (Kaletra) on tacrolimus blood concentration in liver transplantation patients, Liver Transpl, 9, 954, 10.1053/jlts.2003.50171

Mertz, 2009, Drug-drug interaction in a kidney transplant recipient receiving HIV salvage therapy and tacrolimus, Am J Kidney Dis, 54, e1, 10.1053/j.ajkd.2009.01.268

Teicher, 2007, Effect of highly active antiretroviral therapy on tacrolimus pharmacokinetics in hepatitis C virus and HIV co-infected liver transplant recipients in the ANRS HC-08 study, Clin Pharmacokinet, 46, 941, 10.2165/00003088-200746110-00002

Brinkman, 1998, Pharmacokinetic interaction between saquinavir and cyclosporine, Ann Intern Med, 129, 914, 10.7326/0003-4819-129-11_Part_1-199812010-00022

Guaraldi, 2006, Pharmacokinetic interaction between amprenavir/ritonavir and fosamprenavir on cyclosporine in two patients with human immunodeficiency virus infection undergoing orthotopic liver transplantation, Transplant Proc, 38, 1138, 10.1016/j.transproceed.2006.02.013

Neff, 2003, Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease, Liver Transpl, 9, 239, 10.1053/jlts.2003.50054

Frassetto, 2007, Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients, Am J Transplant, 7, 2816, 10.1111/j.1600-6143.2007.02007.x

Di Biagio, 2009, Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient, J Antimicrob Chemother, 64, 874, 10.1093/jac/dkp269

Bickel, 2010, Daily dosing of tacrolimus in patients treated with HIV-1 therapy containing a ritonavir-boosted protease inhibitor or raltegravir, J Antimicrob Chemother, 65, 999, 10.1093/jac/dkq054

Chittick, 2008, Pharmacokinetics of emtricitabine/tenofovir disoproxil fumarate and tacrolimus at steady state when administered alone or in combination, Int J Clin Pharmacol Ther, 46, 627, 10.5414/CPP46627

Eron, 2010, Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials, Lancet, 375, 396, 10.1016/S0140-6736(09)62041-9

Connor, 1988, Acquired immunodeficiency syndrome-associated renal disease in children, J Pediatr, 113, 39, 10.1016/S0022-3476(88)80525-0

Ingulli, 1991, Nephrotic syndrome associated with acquired immunodeficiency syndrome in children, J Pediatr, 119, 710, 10.1016/S0022-3476(05)80284-7

McCulloch, 2008, Kidney disease in HIV-positive children, Semin Nephrol, 28, 585, 10.1016/j.semnephrol.2008.09.001

Rajpoot, 1996, Childhood AIDS nephropathy: a 10-year experience, J Natl Med Assoc, 88, 493

Steel-Duncan, 2008, Renal manifestations in HIV-infected Jamaican children, West Indian Med J, 57, 246

Strauss, 1989, Renal disease in children with the acquired immunodeficiency syndrome, N Engl J Med, 321, 625, 10.1056/NEJM198909073211001

Chaparro, 2008, Proteinuria in children infected with the human immunodeficiency virus, J Pediatr, 152, 844, 10.1016/j.jpeds.2007.11.007

Ahuja, 2004, HIV-associated nephropathy and end-stage renal disease in children in the United States, Pediatr Nephrol, 19, 808, 10.1007/s00467-004-1482-4

Brady, 2010, Declines in mortality rates and changes in causes of death in HIV-1-infected children during the HAART era, J Acquir Immune Defic Syndr, 53, 86, 10.1097/QAI.0b013e3181b9869f

Gordillo, 2009, Outcome of dialysis in children with human immunodeficiency virus infection, Pediatr Nephrol, 24, 171, 10.1007/s00467-008-0976-x

Ray, 1998, Human immunodeficiency virus (HIV)-associated nephropathy in children from the Washington, D.C. area: 12 years’ experience, Semin Nephrol, 18, 396

Neuhaus, 2010, Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV, AIDS, 24, 697, 10.1097/QAD.0b013e3283365356

Ray, 2009, Taking a hard look at the pathogenesis of childhood HIV-associated nephropathy, Pediatr Nephrol, 24, 2109, 10.1007/s00467-009-1155-4

Turner, 1997, A typical hemolytic uremic syndrome in human immunodeficiency virus-1-infected children, Pediatr Nephrol, 11, 161, 10.1007/s004670050249

Gafni, 2006, Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy: impact on bone mineral density in HIV-infected children, Pediatrics, 118, e711, 10.1542/peds.2005-2525

Hazra, 2005, Tenofovir disoproxil fumarate and an optimized background regimen of antiretroviral agents as salvage therapy for pediatric HIV infection, Pediatrics, 116, e846, 10.1542/peds.2005-0975

Riordan, 2009, Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland, Pediatr Infect Dis J, 28, 204, 10.1097/INF.0b013e31818c8d2c

Soler-Palacin, 2011, Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens, AIDS, 25, 171, 10.1097/QAD.0b013e328340fdca

Vigano, 2010, Tenofovir disoproxil fumarate and bone mineral density: a 60-month longitudinal study in a cohort of HIV-infected youths, Antivir Ther, 15, 1053, 10.3851/IMP1650

Pontrelli, 2012, Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors, BMC Infect Dis, 12, 18, 10.1186/1471-2334-12-18

Andiman, 2009, Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors, Pediatr Infect Dis J, 28, 619, 10.1097/INF.0b013e31819ca49a

Patzer, 2008, Nephrotoxicity as a cause of acute kidney injury in children, Pediatr Nephrol, 23, 2159, 10.1007/s00467-007-0721-x

Babiker, 2012, Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study, Clin Trials, 10, S5, 10.1177/1740774512440342

Guyatt, 2008, Going from evidence to recommendations, BMJ, 336, 1049, 10.1136/bmj.39493.646875.AE

Jaeschke, 2008, Use of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive, BMJ, 337, a744, 10.1136/bmj.a744

Guyatt, 2008, Incorporating considerations of resources use into grading recommendations, BMJ, 336, 1170, 10.1136/bmj.39504.506319.80

Schunemann, 2008, Grading quality of evidence and strength of recommendations for diagnostic tests and strategies, BMJ, 336, 1106, 10.1136/bmj.39500.677199.AE

Guyatt, 2008, What is “quality of evidence” and why is it important to clinicians?, BMJ, 336, 995, 10.1136/bmj.39490.551019.BE

Cockcroft, 1976, Prediction of creatinine clearance from serum creatinine, Nephron, 16, 31, 10.1159/000180580

Levey, 2010, Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions, Am J Kidney Dis, 55, 622, 10.1053/j.ajkd.2010.02.337

Rule, 2004, Using serum creatinine to estimate glomerular filtration rate: accuracy in good health and in chronic kidney disease, Ann Intern Med, 141, 929, 10.7326/0003-4819-141-12-200412210-00009

Stevens, 2010, Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) study equations for estimating GFR levels above 60 mL/min/1.73 m2, Am J Kidney Dis, 56, 486, 10.1053/j.ajkd.2010.03.026

Schwartz, 2009, New equations to estimate GFR in children with CKD, J Am Soc Nephrol, 20, 629, 10.1681/ASN.2008030287

Myers, 2006, Recommendations for improving serum creatinine measurement: a report from the Laboratory Working Group of the National Kidney Disease Education Program, Clin Chem, 52, 5, 10.1373/clinchem.2005.0525144

Alves, 2010, Race, kidney disease progression, and mortality risk in HIV-infected persons, Clin J Am Soc Nephrol, 5, 2269, 10.2215/CJN.00520110

Freedman, 1995, Familial predisposition to nephropathy in African-Americans with non-insulin-dependent diabetes mellitus, Am J Kidney Dis, 25, 710, 10.1016/0272-6386(95)90546-4

Gupta, 2004, Prevalence of proteinuria and the development of chronic kidney disease in HIV-infected patients, Clin Nephrol, 61, 1, 10.5414/CNP61001

Brancati, 1997, Risk of end-stage renal disease in diabetes mellitus: a prospective cohort study of men screened for MRFIT. Multiple Risk Factor Intervention Trial, JAMA, 278, 2069, 10.1001/jama.1997.03550230045035

Klag, 1996, Blood pressure and end-stage renal disease in men, N Engl J Med, 334, 13, 10.1056/NEJM199601043340103

Szczech, 2002, Predictors of proteinuria and renal failure among women with HIV infection, Kidney Int, 61, 195, 10.1046/j.1523-1755.2002.00094.x

Tsui, 2007, Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease, Arch Intern Med, 167, 1271, 10.1001/archinte.167.12.1271

Walton, 1975, Nomogram for derivation of renal threshold phosphate concentration, Lancet, 2, 309, 10.1016/S0140-6736(75)92736-1

Garraffo, 1989, Influence of hemodialysis on zidovudine (AZT) and its glucuronide (GAZT) pharmacokinetics: two case reports, Int J Clin Pharmacol Ther Toxicol, 27, 535

Kimmel, 1995, Pharmacokinetics of zidovudine in HIV-infected patients with end-stage renal disease, Blood Purif, 13, 340, 10.1159/000170218

Singlas, 1989, Zidovudine disposition in patients with severe renal impairment: influence of hemodialysis, Clin Pharmacol Ther, 46, 190, 10.1038/clpt.1989.125

Stellbrink, 1993, Zidovudine half-life in haemodialysis patients, AIDS, 7, 141, 10.1097/00002030-199301000-00032

Paoli, 1992, Pharmacodynamics of zidovudine in patients with end-stage renal disease, N Engl J Med, 326, 839, 10.1056/NEJM199203193261216

Gallicano, 1992, Pharmacokinetics of single and chronic dose zidovudine in two HIV positive patients undergoing continuous ambulatory peritoneal dialysis (CAPD), J Acquir Immune Defic Syndr, 5, 242, 10.1097/00126334-199203000-00004

Pachon, 1992, Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis, AIDS, 6, 827, 10.1097/00002030-199208000-00010

Kremer, 1992, Zidovudine pharmacokinetics in five HIV seronegative patients undergoing continuous ambulatory peritoneal dialysis, Pharmacotherapy, 12, 56, 10.1002/j.1875-9114.1992.tb02672.x

US Department of Health and Human Services, Food and Drug Administration, Guidance for industry: pharmacokinetics in patients with impaired renal function—study design, data analysis, and impact on dosing and labeling

Johnson, 1999, Clinical pharmacokinetics of lamivudine, Clin Pharmacokinet, 36, 41, 10.2165/00003088-199936010-00004

Heald, 1996, Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction, Antimicrob Agents Chemother, 40, 1514, 10.1128/AAC.40.6.1514

Bohjanen, 2002, Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis, Antimicrob Agents Chemother, 46, 2387, 10.1128/AAC.46.8.2387-2392.2002

Izzedine, 2001, Pharmacokinetics of abacavir in HIV-1-infected patients with impaired renal function, Nephron, 89, 62, 10.1159/000046045

Grasela, 2000, Pharmacokinetics of single-dose oral stavudine in subjects with renal impairment and in subjects requiring hemodialysis, Antimicrob Agents Chemother, 44, 2149, 10.1128/AAC.44.8.2149-2153.2000

Knupp, 1996, Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis, Clin Pharmacol Ther, 60, 535, 10.1016/S0009-9236(96)90149-6

Singlas, 1992, Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis, Antimicrob Agents Chemother, 36, 1519, 10.1128/AAC.36.7.1519

2012, Videx-EC (didanosine-EC) [package insert]

2012, Emtiva (emtricitabine) [package insert]

Izzedine, 2003, Pharmacokinetics of tenofovir in haemodialysis, Nephrol Dial Transplant, 18, 1931, 10.1093/ndt/gfg327

2013, Truvada (emtricitabine/tenofovir) [package insert]

2012, Viramune (nevirapine) [package insert]

Taburet, 2000, Antiretroviral drug removal by haemodialysis, AIDS, 14, 902, 10.1097/00002030-200005050-00022

Taylor, 2000, Pharmacokinetics of nelfinavir and nevirapine in a patient with end-stage renal failure on continuous ambulatory peritoneal dialysis, J Antimicrob Chemother, 45, 716, 10.1093/jac/45.5.716

Izzedine, 2001, Pharmacokinetic of nevirapine in haemodialysis, Nephrol Dial Transplant, 16, 192, 10.1093/ndt/16.1.192

Izzedine, 2001, Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis, Nephrol Dial Transplant, 16, 643, 10.1093/ndt/16.3.643

2013, Sustiva (efavirenz) [package insert]

Izzedine, 2000, Pharmacokinetics of efavirenz in a patient on maintenance haemodialysis, AIDS, 14, 618, 10.1097/00002030-200003310-00020

Gill, 2000, Efavirenz dosing in patients receiving continuous ambulatory peritoneal dialysis, AIDS, 14, 1062, 10.1097/00002030-200005260-00021

2012, Rescriptor (delavirdine) [package insert]

2012, APTIVUS (tipranavir) [package insert]

Izzedine, 2000, Indinavir pharmacokinetics in haemodialysis, Nephrol Dial Transplant, 15, 1102, 10.1093/ndt/15.7.1102-a

Guardiola, 1998, Indinavir pharmacokinetics in haemodialysis-dependent end-stage renal failure, AIDS, 12, 1395, 10.1097/00002030-199811000-00025

Izzedine, 2001, Pharmacokinetics of ritonavir and saquinavir in a haemodialysis patient, Nephron, 87, 186, 10.1159/000045910

2012, Fortovase (saquinavir) [package insert]

Izzedine, 1999, Pharmacokinetics of nelfinavir in an HIV patient with renal insufficiency, AIDS, 13, 1989, 10.1097/00002030-199910010-00030

Paci-Bonaventure, 2001, Lack of removal of nelfinavir during a haemodialysis session in an HIV-1 infected patient with hepatic and renal insufficiency, Nephrol Dial Transplant, 16, 642, 10.1093/ndt/16.3.642

2011, Lexiva (fosamprenavir) [package insert]

2013, Norvir (ritonavir) [package insert]

Izzedine, 2001, ABT 378/r: a novel inhibitor of HIV-1 protease in haemodialysis, AIDS, 15, 662, 10.1097/00002030-200103300-00024

2013, Kaletra (lopinavir/ritonavir) [package insert]

2013, Reyataz (atazanavir) [package insert]

2003, Fuzeon (enfuvirtide) [package insert]